# Lantern Pharma Inc. (LTRN)

> Source: Nexqual · https://nexqual.com/LTRN · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Lantern Pharma Inc. (LTRN), nexqual.com/LTRN" · informational, not investment advice.

**Price:** USD 0.67 (-0.92% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.67 · day 0.66–0.71 · 52w 0.65–4.34 · market cap null · NCM

## Key facts
- Total return with dividends: 1Y -84.6% vs S&P 500 +18.1%; 5Y -93.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.38, revenue estimate $0K.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -84.6% | -93.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -84.7% | -41.8% |
| Volatility (annualized) | 108.3% | 84.2% |
| Max drawdown | -84.6% (Oct 2025→Oct 2026) | -93.7% (Mar 2024→Oct 2026) |

## Peers
ALXO (ALX Oncology Holdings Inc.) USD 1 +2.04% · IMNM (Immunome, Inc.) USD 17.4 -1.02% · ANNX (Annexon, Inc.) USD 3.6 -6.01% · NKTX (Nkarta, Inc.) USD 1.93 -8.10% · CUE (Cue Biopharma, Inc.) USD 18.67 -4.60%

## More
Full page: https://nexqual.com/LTRN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt